Celltrion
Promote the health and welfare of mankind.
Launch date
Employees
Market cap
AUD52.2b
Enterprise valuation
AUD53m (Public information from Sep 2024)
Share price
KRW195200 068270.KQ
Incheon South Korea (HQ)
Financials
Estimates*
KRW | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 1.8t | 1.9t | 2.3t | 2.2t | 3.6b | 4.4b | 5.3b |
% growth | 64 % | 2 % | 21 % | (5 %) | (100 %) | 24 % | 20 % |
EBITDA | 891.0b | 972.0b | 874.0b | 1.0t | 1b | 1.9b | 2.5b |
% EBITDA margin | 48 % | 51 % | 38 % | 47 % | 28 % | 42 % | 46 % |
Profit | 511.0b | 575.0b | 533.0b | 535.6b | 550m | 1.3b | 1.7b |
% profit margin | 28 % | 30 % | 23 % | 25 % | 15 % | 29 % | 32 % |
EV / revenue | 0.0x | 0.0x | 0.0x | 0.0x | 12.0x | 9.6x | 7.9x |
EV / EBITDA | 0.1x | 0.0x | 0.0x | 0.0x | 42.9x | 22.5x | 17.0x |
R&D budget | 171.4b | 125.8b | 139.7b | 161.1b | - | - | - |
R&D % of revenue | 9 % | 7 % | 6 % | 7 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
* | N/A | N/A | - |
* | $129m | Post IPO Equity | |
$320m | Post IPO Equity | ||
Total Funding | - |